Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing

09.07.25 23:45 Uhr

Werte in diesem Artikel
Aktien

55,50 EUR 0,50 EUR 0,91%

Indizes

6.263,3 PKT 37,7 PKT 0,61%

Hologic (HOLX) closed the most recent trading day at $65.85, moving +1.46% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.61%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 0.95%. Heading into today, shares of the medical device maker had lost 0.37% over the past month, outpacing the Medical sector's loss of 0.67% and lagging the S&P 500's gain of 3.85%.The upcoming earnings release of Hologic will be of great interest to investors. The company's earnings report is expected on July 30, 2025. The company's earnings per share (EPS) are projected to be $1.05, reflecting a 0.94% decrease from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.01 billion, showing a 0.39% drop compared to the year-ago quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.19 per share and revenue of $4.08 billion, indicating changes of +2.7% and +1.16%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Hologic boasts a Zacks Rank of #4 (Sell). In the context of valuation, Hologic is at present trading with a Forward P/E ratio of 15.48. This signifies a discount in comparison to the average Forward P/E of 24.67 for its industry. Also, we should mention that HOLX has a PEG ratio of 2.38. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.28 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 180, putting it in the bottom 28% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Hologic und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Hologic

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Hologic

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Hologic IncShs

Wer­bung

Analysen zu Hologic IncShs

DatumRatingAnalyst
01.08.2019Hologic BuyNeedham & Company, LLC
02.05.2019Hologic BuyNeedham & Company, LLC
31.01.2019Hologic BuyNeedham & Company, LLC
09.10.2018Hologic NeutralUBS AG
01.08.2018Hologic BuyNeedham & Company, LLC
DatumRatingAnalyst
01.08.2019Hologic BuyNeedham & Company, LLC
02.05.2019Hologic BuyNeedham & Company, LLC
31.01.2019Hologic BuyNeedham & Company, LLC
01.08.2018Hologic BuyNeedham & Company, LLC
03.05.2018Hologic BuyNeedham & Company, LLC
DatumRatingAnalyst
09.10.2018Hologic NeutralUBS AG
03.05.2018Hologic HoldCanaccord Adams
03.08.2017Hologic Sector PerformRBC Capital Markets
28.04.2016Hologic HoldNeedham & Company, LLC
07.01.2016Hologic Equal WeightBarclays Capital
DatumRatingAnalyst
30.07.2015Hologic UnderweightBarclays Capital
07.01.2015Hologic UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Hologic IncShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen